Related Experiment Videos
A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice
N Neznanov1, A K Man, H Yamamoto
1The Burnham Institute, La Jolla, California 92037, USA.
Abstract:
Heterozygous female mice carrying a targeted mutation of the Ets2 transcription factor gene were mated with a mouse strain that develops mammary tumors due to the expression of the polyoma virus middle T oncogene. Tumors from females with only one wild-type Ets2 gene were approximately one-half the size of tumors from controls. The smaller size of the tumors was correlated with a more differentiated state of early hyperplastic growths and not to differential growth of the frank tumors or to decreased middle T gene expression. Ets2 may regulate the progression of these aggressive mammary tumors.
Insights
Reduced Ets2 transcription factor levels in mice significantly decreased mammary tumor size. This suggests Ets2 plays a role in the progression of aggressive mammary tumors, impacting their development and differentiation.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Mammary tumors are a significant health concern.
- The Ets2 transcription factor and polyoma virus middle T oncogene are implicated in tumor development.
Purpose of the Study:
- To investigate the role of Ets2 in mammary tumor progression.
- To determine if Ets2 influences tumor size and differentiation.
Main Methods:
- Mating heterozygous Ets2 mutant female mice with mice expressing the polyoma virus middle T oncogene.
- Comparing mammary tumor size and differentiation in mice with one wild-type Ets2 gene versus controls.
Main Results:
- Tumors from mice with one wild-type Ets2 gene were approximately half the size of control tumors.
- Smaller tumor size correlated with a more differentiated state of early hyperplastic growths.
- No significant differences in frank tumor growth or middle T gene expression were observed.
Conclusions:
- Ets2 may regulate the progression of aggressive mammary tumors.
- Reduced Ets2 levels are associated with smaller, more differentiated mammary tumors.